Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Novogratz′s Galaxy Tops Revenue Estimates; Shares Rise (Bloomberg) +++ GALAXY DIGITAL Aktie +5,68%

VANDA Aktie

 >VANDA Aktienkurs 
3.636 EUR    +3.0%    (TradegateBSX)
Ask: 3.874 EUR / 1600 Stück
Bid: 3.728 EUR / 1700 Stück
Tagesumsatz: 1050 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
VANDA Aktie über LYNX handeln
>VANDA Performance
1 Woche: -5,0%
1 Monat: -20,3%
3 Monate: -22,4%
6 Monate: -40,4%
1 Jahr: -25,8%
laufendes Jahr: -43,1%
>VANDA Aktie
Name:  VANDA PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US9216591084 / A0JJT3
Symbol/ Ticker:  VM4 (Frankfurt) / VNDA (NASDAQ)
Kürzel:  FRA:VM4, ETR:VM4, VM4:GR, NASDAQ:VNDA
Index:  -
Profil:  Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central ..
>Volltext..
Marktkapitalisierung:  216.43 Mio. EUR
Unternehmenswert:  87.29 Mio. EUR
Umsatz:  192.57 Mio. EUR
EBITDA:  -152.22 Mio. EUR
Nettogewinn:  -245.35 Mio. EUR
Gewinn je Aktie:  -4.13 EUR
Schulden:  20.38 Mio. EUR
Liquide Mittel:  49.98 Mio. EUR
Operativer Cashflow:  -127.06 Mio. EUR
Bargeldquote:  1.04
Umsatzwachstum:  9.36%
Gewinnwachstum:  -323.53%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  VANDA
Letzte Datenerhebung:  27.10.26
>VANDA Kennzahlen
Aktien/ Unternehmen:
Aktien: 60.46 Mio. St.
Frei handelbar: 94.6%
Rückkaufquote: -
Mitarbeiter: 533
Umsatz/Mitarb.: 0.36 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 183.96%
Bewertung:
KGV: -
KGV lG: -
KUV: 1.18
KBV: 1.16
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 89.32%
Gewinnmarge: -127.41%
Operative Marge: -86.07%
Managementeffizenz:
Gesamtkaprendite: -53%
Eigenkaprendite: -77.81%
>VANDA Peer Group
Gesundheit, Neurologische Erkrankungen/ Schlaganfälle, Psychische Erkrankungen/ Depressionen/ Schizophrenie
 
27.10.26 - 11:54
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting (PR Newswire)
 
NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6%......
21.10.26 - 23:45
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 (PR Newswire)
 
Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2026 on Wednesday, October 28, 2026, after the market closes. Vanda will host a conference call......
20.10.26 - 13:24
France′s Lack of Fiscal Anchor a Concern for Markets, Says Vanda′s Nordvig (Bloomberg)
 
Jens Nordvig, president and co-founder at Vanda, examines the market impact of political instability and riots in France and the options available to the European Central Bank to help the situation. He speaks on “Bloomberg Surveillance.” (Source: Bloomberg)...
19.10.26 - 20:21
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer (GlobeNewswire EN)
 
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer....
15.10.26 - 12:18
Vanda puts anxiety drug program on hold after Phase III setback (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.10.26 - 23:42
Vanda Pharmaceuticals: Aktie bricht nach Misserfolg in Phase-III-Studie ein (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
14.10.26 - 23:42
Vanda Pharmaceuticals stock falls after anxiety drug trial fails (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
14.10.26 - 23:09
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program (PR Newswire)
 
Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an......
09.10.26 - 21:12
Retail Money Shifts From Crypto to Event Contracts, Says Eric Liu: Could This Explain Why Dogecoin and XRP Are Lagging Behind Bitcoin? (24/7 Wall St.)
 
Retail traders are pulling their money and focus away from cryptocurrency, according to Eric Liu, co-founder of Vanda Research, which tracks individual investor trends. If Liu is right, this shift may help explain why Dogecoin (CRYPTO: DOGE) and XRP (CRYPTO: XRP)—two cryptocurrencies mainly driven by retail investors—have fallen more than Bitcoin (CRYPTO: BTC) over the past year. As of October 9, […]...
02.10.26 - 15:15
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting (PR Newswire)
 
WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026. The following will be......
30.09.26 - 13:03
Vanda posts late-stage trial win for HETLIOZ in DSWPD, setting up another label expansion (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.09.26 - 01:48
Vanda Pharmaceuticals: Aktie legt nach positiven Studiendaten kräftig zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.09.26 - 00:48
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder (PR Newswire)
 
Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022) 60% of HETLIOZ® treated participants shifted sleep at least 30 minutes earlier, compared to 15% of the placebo arm WASHINGTON, Sept. 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals......
25.09.26 - 18:39
Yields bite, but ′smart money′ still gorging on AI - Vanda (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.09.26 - 22:18
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
 
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update....
15.09.26 - 17:12
Vanda Pharmaceuticals: Erweiterte Pipeline bei steigenden Kosten und Umsetzungsrisiken (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
11.09.26 - 15:31
Vanda Pharmaceuticals auf Cantor-Konferenz: Psychiatrie-Sparte im Fokus der Wachstumsstrategie (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.09.26 - 22:54
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences (PR Newswire)
 
WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in September 2026: The Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September......
24.08.26 - 13:03
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission (PR Newswire)
 
WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's......
22.08.26 - 21:24
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. (PR Newswire)
 
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural Freedom 250 Grand Prix of Washington, D.......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Tandem bona causa triumphat - Endlich triumphiert die gute Sache. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!